

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
12 February 2004 (12.02.2004)

PCT

(10) International Publication Number
WO 2004/012716 A1

(51) International Patent Classification⁷: **A61K 9/48**,
47/14, 9/107

(21) International Application Number:
PCT/GB2003/003304

(22) International Filing Date: 31 July 2003 (31.07.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0218002.4 2 August 2002 (02.08.2002) GB

(71) Applicant (*for SD only*): **SMYTH, Gyles, Darren**
[GB/GB]; 57-60 Lincoln's Inn Fields, London, WC2A
3LS (GB).

(71) Applicant and

(72) Inventor: **PATEL, Satishchandra Punambhai** [US/US];
27 Yale Court, Livingston, NJ 07039 (US).

(74) Agent: **Smyth, Gyles, Darren**; Mark & Clerk, 57-60 Lin-
coln's Inn Fields, London, WC2A 3LS (GB).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: PHARMACEUTICAL FORMULATION COMPRISING CYCLOSPORIN, PROPYLENE GLYCOL ESTER AND
NON-IONIC SURFACTANT

(57) Abstract: The application discloses a pharmaceutical composition suitable for oral administration in the form of a homoge-
neous solution which on exposure to water or gastrointestinal fluids forms an emulsion having a particle size of less than 5 microns,
the solution comprising: (a) a pharmaceutically effective amount of a cyclosporin, in particular Cyclosporin A, (b) a carrier medium
comprising a mixture of mono- and diesters of propylene glycol with fatty acids having from 8 to 10 carbon atoms or with mixtures
of such fatty acids, wherein the monoester makes up less than 60mol% of the mixture, and (c) a non-ionic surfactant having a hy-
drophilic lipophilic balance (HLB) greater than 10.

WO 2004/012716 A1

PHARMACEUTICAL FORMULATION COMPRISING CYCLOSPORIN, PROPYLENE GLYCOL
ESTER AND NON-IONIC SURFACTANT

Pharmaceutical Compositions

The present invention relates to pharmaceutical compositions, in particular a micro-emulsion concentrate for cyclosporins.

The cyclosporins are a class of cyclic undecapeptides, with important pharmacological activities, in particular immunosuppressive, anti-inflammatory and/or anti-parasitic activities. The first of the cyclosporins to be isolated, and the most commonly known cyclosporin, is Cyclosporin A, formulations of which are commercially available under the trade marks SANDIMMUNE (RTM) and NEORAL (RTM).

The cyclosporins are very lipophilic and hydrophobic compounds, which are sparingly soluble in water, but dissolve readily in organic solvents such as methanol, ethanol, chloroform and the like. The low solubility in water results in extremely low bioavailability of the cyclosporins when administered orally. This may lead to higher dosages being required, with the consequent possibility of undesirable side effects. Therefore, to provide an effective therapeutic concentration of the drug in the body when administered orally represents a considerable challenge. Extensive research has been conducted to find cyclosporin formulations that are effective for oral administration. There are a number of preparations of cyclosporins suitable for oral administration proposed by the prior art.

Prior art formulations of cyclosporins for oral administration have often involved combinations of the cyclosporin with a surfactant, an oil, and a co-surfactant. Such formulations have been intended to be diluted with water prior to drinking. However, this is rather inconvenient, and also the resulting aqueous composition has an unpleasant taste.

In order to alleviate the problems of having to dilute the composition with water prior to oral administration, and the unpleasant taste of the resulting solution, liquid

compositions have been formulated into soft capsule preparations. For example, the formulation commercially available under the trade mark SANDIMMUNE (RTM) is encapsulated in a soft capsule with a gelatine shell. The formulation contains ethanol in order to solubilise the cyclosporin. However, the ethanol can permeate the gelatine shell of the capsule and is volatile at room temperature. This means that the composition of the contents can vary during storage. If too much ethanol is lost, the cyclosporin may precipitate from the composition, with adverse effects on the bioavailability. This results in uncertainties about dosage.

US 4,388,307 discloses compositions comprising a cyclosporin together with at least one of the following components:

- a) a trans-esterification product of a natural or hydrogenated vegetable oil triglyceride and a polyalkylene polyol;
- b) a saturated fatty acid triglyceride; and
- c) a mono- or di-glyceride.

It is preferred that ethanol be used as a further solubilising agent, and the compositions for oral administration disclosed in the Examples all contain ethanol.

US 5,342,625 discloses pharmaceutical compositions comprising cyclosporins in micro-emulsion pre-concentrate and micro-emulsion form. The compositions contain a cyclosporin disposed in a composition comprising a hydrophilic phase, a lipophilic phase and a surfactant. The hydrophilic phase comprises 1,2-propylene glycol or $R_1-(O-(CH_2))_X-OR_2$ wherein R_1 is a C_{1-5} alkyl or a tetrahydrofurfuryl group, R_2 is a C_{1-5} alkyl or a tetrahydrofurfuryl group or is hydrogen, and X is from 1 to 6. The lipophilic phase typically comprises a fatty acid triglyceride. The compositions may contain a C_{1-5} alkanol, such as ethanol, as a co-solvent. However, the compositions disclosed in US 5,342,625 include components which are restricted for pharmaceutical use by several regulatory agencies world-wide, including the FDA, because they are not considered "Generally Recognised As Safe" (GRAS) for oral use.

US 5,759,997 discloses pharmaceutical compositions comprising a cyclosporin, a fatty acid triglyceride, and a glycerol fatty acid partial ester or propylene glycol or sorbitol

complete or partial ester. The compositions may also comprise a viscosity reducer, such as the trans-esterification product of a natural vegetable oil triglyceride and a polyalkylene polyol. Ethanol can also be used, but is less preferred. The compositions may also comprise an emulsifying agent, preferably a tenside having a hydrophilic-lipophilic balance (HLB) of at least 10.

US 6,057,289 discloses pharmaceutical compositions comprising cyclosporin and a carrier comprising

- (a) a cyclosporin solubilising agent consisting essentially of C₆ to C₂₂ fatty acids; and
- (b) a water-soluble non-ionic surfactant.

The surfactant should have a hydrophilic-lipophilic balance (HLB) greater than 10, and suitable surfactants include polyoxyethylene products of hydrogenated vegetable oils, polyethoxylated castor oils or polyethoxylated hydrogenated castor oil, polyoxyethylene-sorbitan-fatty acid esters, polyoxyethylene castor oil derivatives and the like. The compositions are for forming microemulsions upon contact with an aqueous medium.

US 5,858,401 discloses compositions that comprise a cyclosporin, a medium chain monoglyceride of C₆ to C₁₂ fatty acids, having a monoglyceride content of at least 50%, and at least one surfactant. The surfactant may be, for example, polyglycolised glycerides or ethoxylated glycerides having a molecular weight of PEG between 400 and 2000 and a fatty acid chain length between C₆ to C₁₈. The compositions are for forming microemulsions upon contact with an aqueous medium.

WO 00/33862 discloses cyclosporin formulations comprising propylene glycol monoesters of C₆ – C₁₈ fatty acids. The monoester content employed is typically >90%, and usually 100%. Comparative Example 2 of this publication shows that when propyleneglycol laurate with a monoester content of 45-50% is used, the cyclosporin is not solubilised and precipitation and crystal growth occurs after two weeks.

Having regard to the state of the art, it is clear that it is desirable to provide further formulations of cyclosporins suitable for oral administration, and in particular ones which can be formulated in capsules such as soft gelatine capsules, and which are emulsion concentrates (that is, homogeneous solutions which on exposure to water or gastrointestinal fluids form an emulsion having a particle size of less than 5 microns), and preferably microemulsion concentrates, which avoid the use of volatile components such as ethanol, and which utilise compounds which are Generally Recognised As Safe (GRAS).

Another problem in formulating cyclosporin is the potential hygroscopicity of the formulations. It is clearly important to the stability of the formulation to reduce absorption of water by the formulation. However, this is particularly important in the case when the delivery form is a soft gel capsule, because if water is absorbed from the shell of the soft gel capsule then the shell becomes brittle.

There is also a continued need to provide cyclosporin formulations for oral administration which can have high cyclosporin concentrations (thereby reducing the size of capsule required for a given dosage), which exhibit high oral bioavailability, and which are stable (in particular stable against precipitation of the cyclosporin) upon storage. It is also desirable that formulations should have as few components as possible, thereby resulting in ease of manufacture.

The present invention aims to provide cyclosporin compositions which, at least to some extent, satisfy these requirements.

According to the present invention, there is provided a pharmaceutical composition suitable for oral administration in the form of a homogeneous solution which on exposure to water or gastrointestinal fluids forms an emulsion having a particle size of less than 5 microns, the solution comprising:

- (a) a pharmaceutically effective amount of a cyclosporin,

- (b) a carrier medium comprising a mixture of mono- and diesters of propylene glycol with fatty acids having from 8 to 10 carbon atoms or with mixtures of such fatty acids, wherein the monoester makes up less than 60mol% of the mixture, and
- (c) a non-ionic surfactant having a hydrophilic lipophilic balance (HLB) greater than 10.

The present invention is partly based upon the discovery that the carrier medium as defined in (b) above represents a particularly good solvent medium for cyclosporins, and therefore it is possible to avoid co-solvents such as ethanol, propylene glycol, or the like. The compositions according to the present invention accordingly preferably do not have such co-solvents, and in particular preferably do not contain ethanol.

Surprisingly, having regard to the teaching of WO 00/33862, according to the present invention it has been found that, provided a C₈ to C₁₀ fatty acid is used, then effective solubilisation of cyclosporin can be obtained when less than 60%, preferably between 50 and 60%, monoester content is employed. Thus, according to the present invention, the combination of the correct fatty acid and the correct monoester content that allow effective solubilisation of cyclosporin. Furthermore, reducing the monoester content reduces the hygroscopicity of the formulation.

The compositions according to the present invention preferably do not contain appreciable amounts of water, that is, they are substantially water-free.

The compositions according to the present invention exhibit excellent stability upon storage, and high concentrations of cyclosporins in the compositions can be achieved.

The compositions according to the present invention are homogeneous mixtures which exhibit excellent bioavailability of the cyclosporin *in vivo*.

The cyclosporin is preferably Cyclosporin A. The cyclosporin preferably makes up from 1 to 25% by weight of the composition, more preferably makes up from 5 to 20%

by weight of the composition, even more preferably makes up from 10 to 20% by weight of the composition, and most preferably makes up from 15 to 20% by weight of the composition. The cyclosporin is present in the composition of the present invention in pharmaceutically effective amounts. These amounts are well-known in the art. For example, when treating chronic inflammations or provoking an immunosuppressive effect, it is preferred that the daily dose ranges from about 3 mg/kg to about 50 mg/kg.

The carrier medium preferably makes up from 20 to 80% by weight of the composition, more preferably makes up from 35 to 60% by weight of the composition, and most preferably makes up from 40 to 55% by weight of the composition. In the carrier medium, the monoester preferably makes up between 50 and 60mol% of the mixture of mono- and diesters.

In a particularly preferred embodiment, the carrier medium consists of a mixture of mono- and diesters of propylene glycol with capric and caprylic acids. In another particularly preferred embodiment, the carrier medium consists of a mixture of mono- and diesters of propylene glycol with caprylic acid. Suitable products are available commercially as IMWITOR (RTM) 408 and CAPRYOL (RTM) PGMC.

The non-ionic surfactant preferably makes up from 5 to 60% by weight of the composition, more preferably makes up from 20 to 50% by weight of the composition, and most preferably makes up from 30 to 40% by weight of the composition.

The Hydrophilic Lipophilic Balance (HLB) of the non-ionic surfactant is greater than 10, more preferably greater than 12 and most preferably greater than 14.

The non-ionic surfactant must be capable of forming a stable emulsion, preferably a fine emulsion (particle size less than 1 micron), and more preferably a microemulsion, of the composition when it is brought into contact with aqueous fluid, such as in the G.I. tract.

The non-ionic surfactant is preferably selected from the group consisting of: polyoxyethylene products of hydrogenated vegetable oils, polyethoxylated castor oils,

polyethoxylated hydrogenated castor oil, polyoxyethylene-sorbitan-fatty acid esters, and polyoxyethylene castor oil derivatives. Particularly preferred surfactants are set out in **Table 1**. Mixtures of these surfactants can also be used.

Trade Name	Description
TWEEN (RTM) 20	Polyoxyethylene (20) sorbitan monolaurate
TWEEN (RTM) 40	Polyoxyethylene (20) sorbitan monopalmitate
TWEEN (RTM) 60	Polyoxyethylene (20) sorbitan monostearate
TWEEN (RTM) 80	Polyoxyethylene (20) sorbitan monooleate
NIKKOL (RTM) HCO30	PEG-30 hydrogenated castor oil
NIKKOL (RTM) HCO40	PEG-40 hydrogenated castor oil
NIKKOL (RTM) HCO50	PEG-50 hydrogenated castor oil
NIKKOL (RTM) HCO60	PEG-60 hydrogenated castor oil
CREMOPHORE (RTM) RH40	Polyoxyethylene 40 castor oil
CREMOPHORE (RTM) RH60	Polyoxyethylene 60 castor oil
CREMOPHORE (RTM) EL35	Polyoxyethylene 35 castor oil

Table 1

The pharmaceutical compositions according to the present invention may further comprise an antioxidant. This antioxidant, when present, is preferably present in an amount of from 0.01% to 2% by weight of the composition, and more preferably from 0.5 to 1% by weight of the composition. The antioxidant may be any suitable antioxidant, such as are well known to those skilled in the art. Particularly preferred antioxidants are butyl hydroxy anisole (BHA), butyl hydroxy toluene (BHT), and alpha-tocopherol.

Other additives, excipients, and diluents normally used in the pharmaceutical arts may optionally be added to the composition. These include thickening agents, dispersing agents, flavouring agents, sweetening agents, colouring agents, stabilising agents (including pH stabilisers), and preservatives. However, the compositions of the present invention preferably consist only of the components defined in Claim 1, or at least comprise at least 90%, more preferably at least 95%, and more preferably at least 98% by weight of the components defined in Claim 1.

The pharmaceutical compositions according to the present invention may be formulated as a drinking solution, or as a hard or soft capsule. Soft capsule formulations are particularly preferred. Gelatine capsules are also preferred.

The pharmaceutical compositions according to the present invention can be conveniently prepared by uniformly and thoroughly mixing the carrier medium, the cyclosporin, and the surfactant together at room temperature or at slightly elevated temperature, such as a temperature up to 40°C, until a clear solution is obtained, and then cooling the composition to room temperature. The other additives indicated above are then thoroughly admixed therewith. The cyclosporin remains in solution and does not crystallise or precipitate out.

Compositions according to the present invention are preferably for administration to mammals, and especially to humans. It is preferred that the pharmaceutical compositions of the present invention are administered in capsule, liquid-oral, drink solution, or the like form. In a preferred embodiment, the composition is in a form adapted for oral administration in oral unit dosage form. Capsules, e.g., soft or hard gelatine capsules, which represent the preferred oral dosage form, are specially suitable unit dosage forms for oral administration.

Oral unit dosage forms in accordance with the present invention will suitably comprise from 5 to 400 mg and more preferably from 20 to 200 mg, e.g., 25, 50, 100, 125, 150, or 200 mg of cyclosporin. The dosage of the drug and the number of times administered to the patient will vary depending on several factors such as: the age of the patient, the severity of the condition of the patient, and past medical history, and will be a matter to be determined by the attending physician.

When the composition of the present invention is prepared in the form of a soft or hard capsule, the composition may be encapsulated in a gelatine shell which contains any conventional plasticizer. Suitable plasticizers are: glycerine, sorbitol, hexanetriol propylene carbonate, hexane glycol, sorbitans, tetrahydrofuryl alcohol ether, diethylene glycol monoethyl ether, 1,3-trimethyl-2-imidazolidone, dimethylisorbide, and

mixtures of these. However, the plasticizer is not limited to those just mentioned, and any suitable plasticizer can be used.

Encapsulation can be achieved by standard techniques which are well known in the art.

Compositions according to the present invention exhibit high solubility of cyclosporin, thereby reducing the size of the capsule or other oral unit dosage form. They also employ only materials that are GRAS for oral use.

The invention will now be further described with reference to the following Examples, it being understood that these are intended to illustrate the invention, and in no way to limit its scope.

Examples

The examples used the ingredients and in the amounts indicated in **Table 2**.

Cyclosporin A was dissolved in the carrier medium, the surfactant was added, and the mixture was mixed for from 10 to 30 minutes at room temperature until the solution was homogeneous.

The solution was then stored overnight up to 24 hours to ensure that no crystallisation occurred.

Ingredients	Example 1	Example 2	Example 3	Example 4
	Weight/mg	weight/mg	weight/mg	weight/mg
Cyclosporin A	100	25	100	100
Mono/diester of propylene glycol with caprylic acid (IMWITOR 408)	285	100	285	170
Mono/diester of propylene glycol with caprylic acid (CAPRYOL PGMC)				130
Polyoxyethylene 35 castor oil (CREMOPHORE EL35)	195		195	180
Polyoxyethylene 20 sorbitan monolaurate (TWEEN 20)		80		
Alpha tocopherol			5	
TOTAL	580 mg	205 mg	585 mg	580 mg

Table 2

The verify that an emulsion was formed, one part of each composition was added to 10 parts of water and stirred gently. There was formed a fine emulsion having a particle size of less than 5 microns, and the Cyclosporin A did not precipitate or crystallise out.

The compositions are suitable for encapsulation into a hard or soft gelatine capsule.

Comparative Examples

The formulation of Example 1 was compared with analogous examples in which the carrier medium was a diester of propylene glycol with capric/caprylic acids (MIGLYOL (RTM) 840) (Comparative Example 1); a mixture of mono- and diesters of propylene glycol with lauric acid (LAUROGLYCOL FCC) (Comparative Example 2); and a mixture of mono and di-glycerides of capric/caprylic acids (CAPMUL (RTM) MCM) (Comparative Example 3).

The compositions were prepared by mixing the components set out in **Table 3** at room temperature until a clear solution was formed. The resulting solutions were maintained at room temperature for four weeks and then compared. The results are shown in **Table 4**.

Ingredients	Example 1	Comparative Example 1	Comparative Example 2	Comparative Example 3
	weight/mg	weight/mg	weight/mg	weight/mg
Cyclosporin A	100	100	100	100
Mono/diester of propylene glycol with caprylic acid (IMWITOR 408)	285			
Diester of propylene glycol with capric/caprylic acids (MIGLYOL (RTM) 840)		285		
Mono/diester of propylene glycol with lauric acid (LAUROGLYCOL FCC)			285	
Mono/di-glycerides of capric/caprylic acids (CAPMUL(RTM) MCM)				285
Polyoxyethylene 35 castor oil (CREMOPHORE EL35)	195	195	195	195
Alpha tocopherol	5	5	5	5
TOTAL	585 mg	585 mg	585 mg	585 mg

Table 3

Conditions	Example 1	Comparative Example 1	Comparative Example 2	Comparative Example 3
	Observation			
Initial	Clear solution	Hazy solution	Clear solution	Clear solution
4 weeks at 25°C	Clear solution	Precipitation hazy solution	Hazy solution	Hazy solution
4 weeks at 40 °C +75% RH	Clear solution	Precipitation hazy solution	Hazy solution	Hazy solution

Table 4

Hygroscopicity test

Hygroscopicity tests show that whereas propyleneglycol ester of C₈ fatty acid with monoester content about 90% (see Example 8 of WO 00/33862) absorbs 3-4% of moisture from a soft gel capsule, a propyleneglycol ester of C₈ fatty acid with monoester content of between 50 and 60%, as used in the present invention, absorbs only 1-2% moisture.

CLAIMS

1. A pharmaceutical composition suitable for oral administration in the form of a homogeneous solution which on exposure to water or gastrointestinal fluids forms an emulsion having a particle size of less than 5 microns, the solution comprising:
 - (a) a pharmaceutically effective amount of a cyclosporin,
 - (b) a carrier medium comprising a mixture of mono- and diesters of propylene glycol with fatty acids having from 8 to 10 carbon atoms or with mixtures of such fatty acids, wherein the monoester makes up less than 60mol% of the mixture, and
 - (c) a non-ionic surfactant having a hydrophilic lipophilic balance (HLB) greater than 10.
2. A pharmaceutical composition according to Claim 1 wherein the monoester makes up between 50 and 60mol% of the mixture of mono- and diesters.
3. A pharmaceutical composition according to Claim 1 or Claim 2, wherein the cyclosporin makes up from 1 to 25% by weight of the composition.
4. A pharmaceutical composition according to Claim 3 wherein the cyclosporin makes up from 5 to 20% by weight of the composition.
5. A pharmaceutical composition according to any of Claims 1 to 4, wherein the carrier medium makes up from 20 to 80% by weight of the composition.
6. A pharmaceutical composition according to Claim 5, wherein the carrier medium makes up from 35 to 60% by weight of the composition.

7. A pharmaceutical composition according to any of Claims 1 to 6, wherein the non-ionic surfactant makes up from 5 to 60% by weight of the composition.
8. A pharmaceutical composition according to Claim 7, wherein the non-ionic surfactant makes up from 20 to 50% by weight of the composition.
9. A pharmaceutical composition according to any of Claims 1 to 8, wherein said carrier medium consists of a mixture of mono- and diesters of propylene glycol with capric and caprylic acids.
10. A pharmaceutical composition according to any of Claims 1 to 8, wherein said carrier medium consists of a mixture of mono- and diesters of propylene glycol with caprylic acid.
11. A pharmaceutical composition according to any of Claims 1 to 10, wherein the non-ionic surfactant is selected from the group consisting of: polyoxyethylene products of hydrogenated vegetable oils, polyethoxylated castor oils, polyethoxylated hydrogenated castor oil, polyoxyethylene-sorbitan-fatty acid esters, polyoxyethylene castor oil derivatives, and mixtures thereof.
12. A pharmaceutical composition according to Claim 11, wherein the non-ionic surfactant is selected from the group consisting of polyoxyethylene (20) sorbitan monolaurate, polyoxyethylene (20) sorbitan monopalmitate, polyoxyethylene (20) sorbitan monostearate, polyoxyethylene (20) sorbitan monooleate, PEG-30 hydrogenated castor oil, PEG-40 hydrogenated castor oil, PEG-50 hydrogenated castor oil, PEG-60 hydrogenated castor oil, polyoxyethylene 40 castor oil, polyoxyethylene 60 castor oil, polyoxyethylene 35 castor oil, and mixtures thereof.
13. A pharmaceutical composition according to any of Claims 1 to 12, comprising an antioxidant.

14. A pharmaceutical composition according to Claim 13, wherein the antioxidant is present in an amount of from 0.01% to 2% by weight of the composition.
15. A pharmaceutical composition according to Claim 13 or Claim 14, wherein the antioxidant is selected from the group consisting of BHA, BHT, and alpha-tocopherol.
16. A pharmaceutical composition according to any of Claims 1 to 15, wherein the cyclosporin is Cyclosporin A.
17. A pharmaceutical composition according to any of Claims 1 to 16, formulated as a drinking solution.
18. A pharmaceutical composition according to any of Claims 1 to 16 formulated as a hard or soft capsule.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 03/03304

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K9/48 A61K47/14 A61K9/107

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00 33862 A (PHARMASOLUTIONS INC) 15 June 2000 (2000-06-15) cited in the application Comparative example 1 and p.33, 1.20-21 p.1, 1.21-25	1,9,11, 12,16-18
A	WO 98 40051 A (ABBOTT LAB) 17 September 1998 (1998-09-17) the whole document	
A	US 6 294 192 B1 (CHEN FENG-JING ET AL) 25 September 2001 (2001-09-25) the whole document	
A	US 5 645 856 A (EMBLETON JONATHAN KENNETH ET AL) 8 July 1997 (1997-07-08) the whole document	

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

14 November 2003

Date of mailing of the international search report

28/11/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Perez, F

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 03/03304

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0033862 A	15-06-2000	AU 2588500 A	26-06-2000
		BR 9916063 A	22-01-2002
		CA 2354233 A1	15-06-2000
		CN 1338942 T	06-03-2002
		EP 1135150 A1	26-09-2001
		JP 2002531515 T	24-09-2002
		NZ 512287 A	20-12-2002
		PL 348193 A1	06-05-2002
		WO 0033862 A1	15-06-2000
		US 6638522 B1	28-10-2003
		US 6436430 B1	20-08-2002
		ZA 200104585 A	13-06-2002
WO 9840051 A	17-09-1998	EP 0973502 A1	26-01-2000
		JP 2001515491 T	18-09-2001
		WO 9840051 A1	17-09-1998
US 6294192 B1	25-09-2001	AU 2224200 A	14-09-2000
		CA 2365536 A1	31-08-2000
		EP 1158959 A1	05-12-2001
		JP 2002537317 A	05-11-2002
		NZ 513810 A	28-09-2001
		WO 0050007 A1	31-08-2000
		US 2003077297 A1	24-04-2003
		US 2003104048 A1	05-06-2003
US 5645856 A	08-07-1997	US 2002012680 A1	31-01-2002
		AT 228831 T	15-12-2002
		AU 686767 B2	12-02-1998
		AU 1897495 A	03-10-1995
		CA 2185347 A1	21-09-1995
		DE 69529060 D1	16-01-2003
		DE 69529060 T2	09-10-2003
		DK 750495 T3	06-01-2003
		EP 1205180 A2	15-05-2002
		EP 0750495 A1	02-01-1997
		ES 2186715 T3	16-05-2003
		WO 9524893 A1	21-09-1995
		JP 10503750 T	07-04-1998
		PT 750495 T	28-02-2003
		US 6096338 A	01-08-2000